Second Look Lab — Research Brief: Bezafibrate as a candidate geroprotector, with a forward prediction ledger of 50 ongoing trials
Year: 2026
Type: preprint
Abstract: Hypothesis-generating research brief from Second Look Lab, an independent computational drug-repurposing project. Bezafibrate (a pan-PPAR agonist approved for decades as a lipid-lowering drug) was ranked by our cross-disease longevity screen (genetics-weighted Open Targets evidence, network neighbors, hallmarks-of-aging tagging) as an under-explored candidate geroprotector relative to metformin, GLP-1 agonists and SGLT2 inhibitors, which the same screen recovers as known candidates. This is a computational hypothesis only, not medical advice and not clinical evidence. Proposed next step: testing in the NIA Interventions Testing Program (ITP). Integrity: SHA-256 of the PDF = a68a06d1441a42d5a305f3c9e5f28b410a41727f050872af4cc023bda700c0d4, timestamped with OpenTimestamps (Bitcoin) on 2026-11-09. Related: Second Look Lab brief on NO-cGMP, DOI 10.5281/zenodo.24078249. Contact: [email protected] Also included: predictions_ledger_2026-11-09.csv, a forward prediction ledger of 50 ongoing phase 2/3 clinical trials (results not yet published) with our engine's FAVORABLE / NEUTRAL / SKEPTICAL call for each, recorded before the results are known (SHA-256 d1bf55440f3b8e5a6a177f58e8a1217b4448b06ef639a46e6241ba0fd6419b68, OpenTimestamps 2026-11-09).
Author: Second Look Lab
Language: English
Subfield: Aging
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7225645886
Cites:
Cited by:
Related to: